Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing-by. My name is Amy, and I will be your conference operator for today.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 99,900 | $7,621,371 | 0.07% | ||
| 2. | Royce & Associates Chuck Royce | 90,027 | $6,868,160 | 0.07% | |
| 3. | Neo Ivy Capital Renee Yao | 4,452 | $339,643 | 0.11% | |
| 4. | Bayforest Capital Theodoros Tsagaris | 7,054 | $268,846 | +256% | 0.22% |
| 5. | RWC Asset Management Tord Stallvik (Ceo) | 3,420 | $260,912 | -2% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.29 | 10,000 | Director | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | Director | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | Director | 15,900 | 2022-11-01 | Filing | |
| $17.53 | 20,000 | Director | 281,021 | 2022-10-31 | Filing | |
| $17.69 | 45,000 | Director | 98,265 | 2022-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $72.78 | 4,201 | Officer, Director | 233,924 | 2025-05-01 | Filing | |
| $72.24 | 2,629 | Officer, Director | 238,125 | 2025-05-01 | Filing | |
| $71.30 | 600 | Officer, Director | 233,924 | 2025-04-15 | Filing | |
| $70.54 | 2,896 | Officer, Director | 234,524 | 2025-04-15 | Filing | |
| $69.62 | 3,334 | Officer, Director | 237,420 | 2025-04-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,268,122 | $1,393,675,028 | 0.03% | |
| 2. | 16,048,882 | $1,224,369,208 | 0.03% | |
| 3. | 2,313,217 | $176,475,325 | 0.5% | |
| 4. | 2,013,329 | $153,853,350 | 0.17% | |
| 5. | 1,755,373 | $133,917,407 | 0.08% |
News See All
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy
Uncertainty is around every corner of the U.S. stock market, affecting investors’ decisions.
Billionaire George Soros' 10 Mid-Cap Stocks With Huge Upside Potential
George Soros is one of the most successful investors in the stock market’s history. He founded the Soros Fund Management, which currently manages over $6.6 billion in assets.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Best Long Term Growth Stocks to Buy According to Billionaires
As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and...
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Insmed Incorporated (NASDAQ:INSM) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Pam, and I will be your conference operator today.
Will Insmed Incorporated’s (INSM) New Drugs be Able to Peak Sales?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
Billionaire Hedge Funds
